Decreased S100-beta protein in schizophrenia: Preliminary evidence

Schizophrenia Research

Volumn 43, Issue 2-3, 2000, Pages 91-95

  Gattaz, Wagner F ^a   Lara, Diogo R ^b   Elkis, Helio ^a   Portela, Luis V ^b   Gonçalves, Carlos A ^b   Tort, Adriano B ^b   Henna, Jorge ^a   Souza, Diogo O ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

Author keywords

Brain development; Phospholipase A2; S100 protein; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; PHOSPHOLIPASE A2; PROTEIN S 100;

ADULT; ARTICLE; BRAIN DEVELOPMENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; BRAIN; CYTOSOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PHOSPHOLIPASES A; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; S100 PROTEINS; SCHIZOPHRENIA;

EID: 0034674725     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00146-2     Document Type: Article

References (34)

1. Azmitia E.C., Griffin S.T., Marshak D.R., Van Eldik L.J., Whitaker-Azmitia P.M. S100B and serotonin: a possible astrocytic-neuronal link to neuropathology of Alzheimer's disease. Prog. Brain Res. 94:1992;459-473.
2. Brunner J., Gattaz W.F. Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats. Psychiatry Res. 58:1995;165-169.
3. Brunner J., Gattaz W.F. Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats - possible implications for schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 246:1995;13-16.
4. Ciccarelli R., Casabona G., D'Alimonte I., Di Iorio B., Caciagli F., Nicoletti F. Stimulation of nerve growth factor and S100 protein production from rat cultured astrocytes by adenosine A1 and group II metabotropic glutamate receptors. Drug Dev. Res. 43:1998;51.
5. Deicken R.F. Functional magnetic resonance imaging and magnetic resonance spectroscopy in schizophrenia. Gattaz W.F., Häfner. Search for the Causes of Schizophrenia. vol. IV:1999;307-322 Springer, New York.
6. Fagnart O.C., Sindic C.J., Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin. Chem. 34:(7):1988;1387-1391.
7. Gattaz W.F., Brunner J. Phospholipase A2 and the hypofrontality hypothesis of schizophrenia. Prostaglandins Leukotrienes Essent. Fatty Acids. 55:1996;109-113.
8. Gattaz W.F., Cairns N.J., Levy R., Forstl H., Braus D.F., Maras A. Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 246:(3):1996;129-131.
9. Gattaz W.F., Hübner, Nevalainen T.J., Thuren T., Kinnunen P.K.J. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 28:1990;495-501.
10. Gattaz W.F., Köllisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry. 22:1987;421-426.
11. Gattaz W.F., Maras A., Cairns N.J., Levy R., Forstl H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry. 37:1995;13-17.
12. Gattaz W.F., Steudle A., Maras A. Increased platelet phospholipase A2 in schizophrenia. Schizophr. Res. 16:1995;1-6.
13. Griffin W.T.S., Stanley E.C., Ling C., White J., Macleod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acd. Sci. USA. 86:1989;7611-7619.
14. Hansson L.O., Djuren E., Dijlai-Merzog R., Nilsson B., Hansson J. S100B: a prognostic marker in malignant melanoma. Clin. Chem. 44:1998;46-47.
15. Iager A.C., Kirch D.G., Wyatt R.J. A negative symptom rating scale. Psychiatry Res. 16:1985;27-36.
16. Ingebrigtsen T., Romner B. Serial S100 protein serum measurements related to early magnetic resonance imaging after minor head injury. J. Neurosurg. 85:1996;945-948.
17. Ingebrigtsen T., Romner B., Kongstad P., Langbakk B. Increased serum concentrations of protein S-100 after minor head injury - a biochemical marker with prognostic value? J. Neurol. Neurosurg. Psychiatry. 59:1995;103-104.
18. Jankovic B.D., Djordjijevic D. Differential appearance of autoantibodies to human brain S100 protein - neuron specific enolase and myelin basic protein in psychiatric patients. Int. J. Neurosci. 60:1991;119-127.
19. Lara D.R., Souza D.O. Schizophrenia: a purinergic hypothesis. Med. Hypoth. 1999;. in press.
20. Marshak D.R. S100 beta as a neurotrophic factor. Prog. Brain Res. 86:1990;169-181.
21. Missler U., Wandiger K.P., Wiesmann M., Kaps M., Wesel K. Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. Acta Neurol. Scand. 96:1997;142-144.
22. Newman-Tancredi A., Gauvadan S., Conte C., Chaput C., Touzard M., Verriele L., Audinot V., Millan M.J. Agonist and antagonist actions of antipsychotic agents at 5HT1A receptors: a (35S)GTPgammaS binding study. Eur. J. Pharmacol. 335:1998;245-256.
23. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., Wolkin A., Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 34:1993;641-649.
24. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Arch. Gen. Psychiatry. 54:1997;487-494.
25. Schäfer B.W., Heizmann C.W. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 21:1996;134-140.
26. Singh V.K. Studies of neuroimmune markers in Alzheimer'disease. Mol. Neurobiol. 1:(3):1994;73-81.
27. Slater P., Doyle C.A., Deakin J.F. Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. J. Neural Transm. 105:1998;305-315.
28. Tacconi M.T. Neuronal death: is there a role for astrocytes? Neurochem. Res. 23:1998;759-765.
29. Van Eldik L.J., Zimmer D.B. Secretion of S100 from rat c6 glioma cells. Brain Res. 436:1978;367-370.
30. Weinberger D.R. From neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
31. Whitaker-Azmitia P.M., Murphy R., Azmitia E.C. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor protein S100 and alters astroglial morphology. Brain Res. 528:1990;155-158.
32. Wiesmann W., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., Kirchner H. Elevated plasma levels of S-100b protein in schizophrenia patients. Biol. Psychiatry. 45:1999;1508-1511.
33. Wu T., Angus C.W., Yao X.L., Logun C., Shalhamer J.H. P11, a unique member of the S100 family of calcium-binding proteins, interacts with and inhibits the activity of the 85-kDA cytosolic phospholipase A2. J. Biol. Chem. 272:1997;17145-17153.
34. Zimmer D.B., Cornwall E.H., Landar A., Song W. The S100 protein family: history, function, and expression. Brain Res. Bull. 37:1995;417-429.